LABORATORY DIAGNOSIS OF RHEUMATOID ARTHRITIS


如何引用文章

全文:

开放存取 开放存取
受限制的访问 ##reader.subscriptionAccessGranted##
受限制的访问 订阅或者付费存取

详细

The determination of IgM rheumatoid factor (IgM RF) plays a large role in the diagnosis of rheumatoid arthritis (RA). IgM RF-positive patients are predisposed to severe RA. The current markers of the latter include anti-cyclic citrullinated peptide (anti-CCP) antibodies and anti-modified citrullinated vimentin (MCV) antibodies, the sensitivity and specificity of which were higher than IgM RF. RF and anti-CCP and anti-MCV antibodies are markers for predisposition to systemic manifestations and destructive changes in the affected joints and for the efficiency of a chosen treatment policy.

全文:

受限制的访问

作者简介

N. Shilkina

Yaroslavl State Medical Academy

Email: shilkin39@mail.ru
MD

M. Voronina

Yaroslavl State Medical Academy

Candidate of Medical Sciences

A. Vinogradov

Yaroslavl State Medical Academy

Candidate of Medical Sciences

参考

  1. Александрова Е.Н., Новиков А.А., Насонов Е.Л. Клиническое значение антител к циклическому цитруллинированному пептиду: новые данные // Клин. мед. - 2007; 85 (8): 4-9.
  2. Каратеев Д.Е., Александрова Е.Н., Демидова Н.В. и др. Антицитруллиновые антитела и данные магнитно-резонансной томографии суставов кисти у больных ранним артритом // Тер. арх. - 2008; 80 (10): 72-7.
  3. Насонов Е.Л. Фармакотерапия ревматоидного артрита в эру генноинженерных биологических препаратов // Тер. арх. - 2007; 74 (5): 5-8.
  4. Насонова В.А., Фоломеева О.М., Эрдес Ш.Ф. Ревматические заболевания в Российской Федерации в начале XXI века глазами статистики // Тер. арх. -2009; 81 (9): 5-10.
  5. Тогизбаев Г., Новиков А.А., Каратеев Д.Е. Прогностическое значение антител к циклическому цитруллинированному пептиду (АЦЦП) при раннем недифференцированном артрите. // Мат. V съезда ревматологов России. - М., 2009; 112; 429.
  6. Bang H., Egerer K., Gauliard A. et al. Mutation and citrullination modifies vimentin to a novel autoantigen for rheumatoid arthritis // Arthr. Rheum. - 2007; 56 (8): 2503-11.
  7. Bobbio-Pallavicini F., Caporali R., Bugatti S. et al. What can we learn from treatment induced changes in rheumatoid factor and anti-citrullinated peptide antibodies? // J. Rheumatol. - 2008; 35 (10): 1903-6.
  8. Dejaco C., Klotz W., Larcher H. et al. Diagnostic value of antibodies against a modified citrullinated vimentin in rheumatoid arthritis // Arthr. Res. Ther. - 2006; 4 (8): 119.
  9. Mathsson L., Mullazehi M., Wick M. et al. Antibodies against citrullinated vimentin in rheumatoid arthritis: higher sensitivity and extended prognostic value concerning future radiographic progression as compared with antibodies against cyclic citrullinated peptides // Arthr. Rheum. - 2008; 58 (1): 36-45.
  10. Mutlu N., Bicakcigil M., Tasan D. et al. Comparative performance analysis of different anti-citrullinated protein assays in the diagnosis of rheumatoid arthritis // J. Rheumatol. - 2009; 36 (3): 491-500.
  11. Nicaise-Roland P., Grootenboer Mignot S. et al. Antibodies to mutated citrullinated vimentin for diagnosing rheumatoid arthritis in anti-CCP-negative patients and for monitoring infliximab therapy // Arthr. Res. Ther. - 2008; 10 (6): 142.
  12. Quartuccio L., Fabris M., Salvin S. et al. Rheumatoid factor positivity rather then ant-CCP positivity, a lower disability and a lower number anti-TNF agents failed are associated with response to Rituximab in rheumatoid arthritis // Rheumatology. - 2009; 48 (5): 1557-9.
  13. Ronnelid J., Wick M., Lampa J. et al. Longitudinal analysis of citrullinated protein/peptide antibodies (anti-CP) during 5 year follow up in early rheumatoid arthritis: anti-CP status predicts worse disease activity and greater radiological progression // Ann. Rheum. Dis. - 2005; 64(12): 1744-9.
  14. Sghiri R., Bouajina E., Bargaoui D. et al. Value of anti-mutated citrullinated vimentin antibodies in diagnosing rheumatoid arthritis // Rheumatol. Int. - 2008; 29 (1): 59-62.
  15. Soos L., Szekanecz Z., Szabo Z. et al. Clinical evaluation of anti-mutated citrullinated vimentin by ELISA in rheumatoid arthritis // J. Rheumatol. - 2007; 34 (8): 1658-63.
  16. Ursum J., Nielen M., van Schaardenburg D. et al. Antibodies to mutated citrullinated vimentin and disease activity score in early arthritis: a cohort study // Arthr. Res. Ther. - 2008; 10 (1): 12.
  17. Wagner E., Skoumal M., Bayer P. et al. Antibody against mutated citrullinated vimentin: a new sensitive marker in the diagnosis of rheumatoid arthritis // Rheumatol. Int. - 2009; 29 (1): 1315-21.

补充文件

附件文件
动作
1. JATS XML
下载
##common.cookie##